Efungumab

Drug Profile

Efungumab

Alternative Names: hsp90 grAB; Mycograb

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator NeuTec Pharma
  • Class Antifungals; Monoclonal antibodies
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Candidiasis

Highest Development Phases

  • Discontinued Breast cancer; Candidiasis

Most Recent Events

  • 05 Oct 2010 Discontinued - Phase-III for Candidiasis in European Union (IV)
  • 05 Oct 2010 Discontinued - Phase-III for Candidiasis in USA (IV)
  • 03 Jun 2010 Phase-III development is ongoing in USA and European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top